Skip to main content
Premium Trial:

Request an Annual Quote

GeneNews' Q3 Revenues Dip on Lower Licensing Revenues

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – GeneNews reported after the close of the market Monday that its third-quarter revenues dropped more than 50 percent on lower licensing revenue year over year.

The Toronto-based firm brought in total revenues of C$166,515 (US$163,309) for the three-month period ended Sept. 30, compared to C$362,964 for the third quarter of 2009. Its license revenue declined to C$162,619 from C$311,684 year over year.

GeneNews' net loss for the quarter was C$1.1 million, or C$.02, compared to a net loss of C$1.4 million, or C$.02 per share, for Q3 2009.

Its R&D spending declined to C$414,966 from C$613,540, and its SG&A expenses dropped to C$374,382 from C$513,495.

The firm sells its ColonSentry genetic test for colorectal cancer in Canada, and it is preparing for a launch of the test in the US and Asia.

Last week, GeneNews raised C$2.1 million in two concurrent private placements aimed at supporting sales and marketing of ColonSentry.

GeneNews finished the quarter with C$477,510 in cash and cash equivalents, C$485,691 in restricted cash, and C$350,080 in short-term investments.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.